Europe electronic drug delivery systems market is projected to register a CAGR of 9.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Europe Electronic Drug Delivery Systems Market By Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Europe electronic drug delivery systems market are:
• High prevalence of various chronic disorders
• Increase in geriatric patient pool susceptible to cardiovascular and respiratory disorders
Market Players:
The key market players for Europe electronic drug delivery systems market are listed below:
• AstraZeneca
• Amgen Inc.
• Ypsomed AG
• Merck KGaA
• Bayer AG
• Nemera
• F. Hoffmann-La Roche Ltd
• AptarGroup, Inc.
• Novo Nordisk A/S.
• ViCentra B.V.
• Medtronic
• United Therapeutics Corporation
• Companion Medical
• Tandem Diabetes Care, Inc.
• Debiotech S.A.
• Canè S.p.A
• Insulet Corporation
• BD
• Findair Sp. z o. o.
• B. Braun Melsungen AG
• West Pharmaceutical Services, Inc.